



APCCC Detailed Program as of February 2015* *All speakers and talks confirmed. But changes to the program may occur at a later stage		
Thursday 12th March 2015		
Time	Session	Speakers
10:00	Welcome Address: T. Cerny (St.Gallen) and H. Soule (PCF) and Europa Uomo representative (K. Mastris)	
10:30 – 12:00 Session 1	Current treatment options: State of the Art <ul style="list-style-type: none"> • Role of new endocrine agents in APC • Role of chemotherapy in the management of APC • Role of immunotherapy in APC • Sequencing or combination – How to make best use of the available agents 	Chairs: S. Gillissen and M. Gleave Talk: J. de Bono Talk: E. Small Talk: C. Drake Talk: E. Efstathiou
12:00 – 13:00 Lunch		
13:00 – 14:00 Session 2	Bone metastases: Best management strategies <ul style="list-style-type: none"> • How to best prevent skeletal related events (SRE's) in the era of novel treatment options • How to make best use of radium-223 • Early detection and treatment of patients with malignant spinal cord compression • Patients with DIC and bone marrow failure 	Chairs: A. Heidenreich and O. Sartor Talk: M. Smith Talk: C. Parker Talk: A. Omlin Talk: G. Daugaard
COFFEE BREAK		
14:30 – 16:30 Session 3	Debates: What is the role of hormonal manipulations without proven survival benefit? <p style="text-align: center;">Audience Vote</p> <ul style="list-style-type: none"> • At progression after ADT: Is an androgen receptor inhibitor without proven survival benefit useful? <ul style="list-style-type: none"> ○ Pro ○ Contra ○ Arbiter <p style="text-align: center;">Audience Vote</p> <ul style="list-style-type: none"> • Single agent steroids: "Dead or Alive"? <ul style="list-style-type: none"> ○ Alive ○ Dead ○ Arbiter <p style="text-align: center;">Audience Vote</p> <ul style="list-style-type: none"> • Ketoconazole: "Dead or Alive"? <ul style="list-style-type: none"> ○ Alive ○ Dead ○ Arbiter <p style="text-align: center;">Audience Vote</p> <ul style="list-style-type: none"> • Estrogens/Estramustine: "Dead or Alive"? <ul style="list-style-type: none"> ○ Alive ○ Dead ○ Arbiter <p style="text-align: center;">Audience Vote</p>	Chair: B. Tombal and G. Attard Talk: A. Heidenreich Talk: G. Attard Arbiter: N. Shore Talk: C. Parker Talk: H. Suzuki Arbiter: W. Oh Talk: A. Sella Talk: G. Attard Arbiter: TBA Talk: K. Fizazi Talk: D. Olmos Arbiter: E. Small
COFFEE BREAK		



17:00 – 18:30 Session 4	<p>Management of special clinical situations</p> <ul style="list-style-type: none"> • When to use radiotherapy in metastatic APC • Management of local complications in APC • Small cell and anaplastic prostate cancer • Meningeal carcinomatosis and brain metastases • Management of young (<55) and old (>85) and/or frail patients • Patients with BRCA1/2 and other germline mutations 	<p>Chairs: M. Hussain and C. Parker Talk: N. James Talk: A. Heidenreich Talk: H. Beltran Talk: S. Nilsson Talk: I. Davis Talk: R. Eeles</p>
------------------------------------	---	--

Friday 13th March 2015		
Time	Session	Speakers
08:00 – 09:45 Session 5	<p>Management of castration-sensitive metastatic prostate cancer</p> <ul style="list-style-type: none"> • Use of LHRH antagonists and single agent AR-Antagonists • Intermittent versus continuous ADT • When to use combined androgen blockade • Bone targeting agents in castration-sensitive metastatic prostate cancer • What's the role of docetaxel in the management of castration-sensitive metastatic prostate cancer? 	<p>Chairs: C. Sweeney and N. James Talk: B. Tombal Talk: M. Hussain Talk: H. Akaza Talk: M. Smith Talk: K. Fizazi</p>
COFFEE BREAK		
10:15 – 11:30 Session 6	<p>Molecular characterisation of APC – Relevance today!</p> <ul style="list-style-type: none"> • Androgen receptor and other steroid receptors: The key drivers of APC? • Current state of molecular characterisation of prostate cancer • Serum based biomarkers and CTCs • Smarter Clinical Trials: Translating biology into Therapeutics 	<p>Chairs: J. Schalken and W. Oh Talk: P. Nelson Talk: A. Chinnaiyan Talk: M. Rubin Talk: M. Hussain</p>
COFFEE BREAK		
11:45 – 12:45 Session 7	<p>M0 CRPC – An overview and debate</p> <ul style="list-style-type: none"> • What imaging and when in M0 CRPC • What treatments are recommended for M0 CRPC? • Patients with M0 CRPC should receive novel survival prolonging treatments <p style="text-align: center;">Audience vote</p> <p>○ Pro</p> <p>○ Contra</p> <p style="text-align: center;">Audience vote</p>	<p>Chairs: N. Shore and E. Efstathiou Talk: F. Lecouvet Talk: I. Davis Talk: M. Gleave Talk: B. Tombal</p>
12:45 – 13:45 Lunch		



13:45 – 15:15 Session 8	<p>Monitoring of Disease Activity: A challenging task</p> <ul style="list-style-type: none"> • Current imaging for APC – An unsolved daily clinical problem: The radiologists view • Current imaging for APC – An unsolved daily clinical problem: The nuclear medicine view • Prostate Cancer Working Group Criteria – The next generation • When to change treatment for APC patients in daily practice 	<p>Chairs: T. Beer and F. Lecouvet Talk: A. Padhani</p> <p>Talk: S. Fanti</p> <p>Talk: H. Scher</p> <p>Talk: M. de Santis</p>
COFFEE BREAK		
15:45 – 17:15 Session 9	<p>How to transfer study results into clinical practice</p> <ul style="list-style-type: none"> • Interpreting clinical trials: New concepts, old pitfalls • Factors that drive clinical decision making • Duration of response to ADT and how this informs us clinically • Shift from prognostication to prediction in APC: Are we ready? 	<p>Chairs: E. Small and J. de Bono Talk: S. Halabi</p> <p>Talk: O. Sartor Talk: C. Sweeney</p> <p>Talk: C. Logothetis</p>
COFFEE BREAK		
17:45 – 18:45 Session 10	<p>Debate: Abiraterone or Enzalutamide as first-line treatment</p> <ul style="list-style-type: none"> ○ Pro Abiraterone ○ Pro Enzalutamide ○ Arbiter <p>Debate: Chemotherapy before use of survival prolonging novel endocrine agents</p> <ul style="list-style-type: none"> ○ Pro chemotherapy ○ Contra chemotherapy ○ Arbiter 	<p>Chair: K. Fizazi and C. Logothetis Talk: W. Oh Talk: T. Beer Arbiter: C. Sternberg</p> <p>Talk: A. Heidenreich Talk: H. Scher Arbiter: J. de Bono</p>

Saturday 14th of March 2015		
Time	Session	Speakers
Moderation: I. Tannock and B. Tombal Protocol: A. Omlin		
09:00 – 10:30	Consensus Panel – Discussion and votes on consensus questions – Part 1	ALL PANEL MEMBERS
COFFEE BREAK		
11:00 – 13:00	Consensus Panel – Discussion and votes on consensus questions – Part 2	ALL PANEL MEMBERS
Closing Remarks: S. Gillessen And save the date Advanced Prostate Cancer Consensus Conference XX.XX.2017		